These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2521268)

  • 1. Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine.
    Hood WB
    Am J Cardiol; 1989 Jan; 63(2):46A-53A. PubMed ID: 2521268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors.
    Wood MA; Hess ML
    Am J Med Sci; 1989 Feb; 297(2):105-13. PubMed ID: 2521982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.
    Packer M
    Am J Cardiol; 1989 Jan; 63(2):41A-45A. PubMed ID: 2642629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new inotropic phosphodiesterase inhibitors.
    el Allaf D; D'Orio V; Carlier J
    Arch Int Physiol Biochim; 1984 Nov; 92(4):S69-79. PubMed ID: 6085243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General overview and update of positive inotropic therapy.
    Leier CV
    Am J Med; 1986 Oct; 81(4C):40-5. PubMed ID: 2946223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some new positive inotropic agents.
    Andersson KE
    Acta Med Scand Suppl; 1986; 707():65-73. PubMed ID: 2874692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic achievements of phosphodiesterase inhibitors and the future.
    Jewitt DE
    Eur Heart J; 1989 Aug; 10 Suppl C():53-9. PubMed ID: 2680498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
    Colucci WS; Wright RF; Braunwald E
    N Engl J Med; 1986 Feb; 314(6):349-58. PubMed ID: 2418353
    [No Abstract]   [Full Text] [Related]  

  • 9. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
    Weber KT; Janicki JS; Jain MC
    J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central and regional hemodynamic effects of oral enoximone in congestive heart failure: a double-blind, placebo-controlled study.
    Leier CV; Lima JJ; Meiler SE; Unverferth DV
    Am Heart J; 1988 May; 115(5):1051-9. PubMed ID: 2966546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group.
    Narahara KA
    Am Heart J; 1991 May; 121(5):1471-9. PubMed ID: 1826806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hemodynamic response to low dose enoximone (MDL 17,043): an oral dose-range study.
    Gilbert EM; Bristow MR; Mason JW
    Am J Cardiol; 1987 Aug; 60(5):57C-62C. PubMed ID: 2956870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs.
    Vandeplassche GM; Hermans CF; de Chaffoy de Courcelles DR; D'Aubioul JA; Wouters LJ; De Clerck FF
    J Cardiovasc Pharmacol; 1992 May; 19(5):714-22. PubMed ID: 1381769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoximone and milrinone--inotropic vasodilators for severe heart failure.
    Drug Ther Bull; 1991 May; 29(10):39-40. PubMed ID: 1834448
    [No Abstract]   [Full Text] [Related]  

  • 15. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone].
    Holubarsch C; Hasenfuss G; Thierfelder L; Heiss HW; Just H
    Z Kardiol; 1991; 80 Suppl 4():35-40. PubMed ID: 1833895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators.
    Colucci WS; Sonnenblick EH; Adams KF; Berk M; Brozena SC; Cowley AJ; Grabicki JM; Kubo SA; LeJemtel T; Littler WA
    J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):113A-118A. PubMed ID: 8376682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal.
    Monrad ES; Baim DS; Smith HS; Lanoue AS; Silverman KJ; Gervino EV; Grossman W
    Circulation; 1986 Mar; 73(3 Pt 2):III205-12. PubMed ID: 3510776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
    Packer M; Carver JR; Rodeheffer RJ; Ivanhoe RJ; DiBianco R; Zeldis SM; Hendrix GH; Bommer WJ; Elkayam U; Kukin ML
    N Engl J Med; 1991 Nov; 325(21):1468-75. PubMed ID: 1944425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Enoximone].
    Ventura G
    Medicina (Firenze); 1990; 10(2):191-3. PubMed ID: 2148796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.